Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia
Open Access
- 18 May 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 14 (9), 1667-1677
- https://doi.org/10.1038/sj.cdd.4402168
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activityBlood, 2006
- Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fractionBlood, 2006
- NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemiaBlood, 2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Drug resistance in cancer: Principles of emergence and preventionProceedings of the National Academy of Sciences of the United States of America, 2005
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsBlood, 2003
- BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Blood, 2003
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001